Thanks, Mr. Chair.
Thanks to my NDP colleague for that.
Mr. Labrie, in your initial comments in this section you mentioned that drugs increased 19% in 2016. I wonder if you can just elaborate on that. You also indicated that we should not support the PMPRB drug pricing recommendations. I got your details as to why. Is there anything else you'd like to elaborate on in that area, since we're not manufacturing them here in Canada?